Phase 1/2a PTT-936 Trial of ALPK1 Activator in Solid Tumors

This study evaluates the safety, dosage, and efficacy of PTT-936, an ALPK1 activator, administered weekly as monotherapy or with anti-PD-1/L1 every three weeks. It enrolls patients with locally advanced or metastatic solid tumors to define an effective treatment strategy in a first-in-human trial conducted by Pyrotech Therapeutics.